137 results
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
21 Feb 24
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD
4:34pm
Securities Litigation Reform Act of 1995. These include statements regarding Catalyst’s expectations, beliefs, plans, or objectives regarding the intended
8-K
EX-99.1
CPRX
Catalyst Pharmaceuticals Inc
9 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering of Common Stock
5:15pm
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These include
8-K
EX-99.2
CPRX
Catalyst Pharmaceuticals Inc
5 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5:23pm
contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These include statements regarding
8-K
EX-99.1
kri9ldvllbyaeoxq
5 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5:23pm
8-K
EX-1.1
ybikko1d 79o
5 Jan 24
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5:23pm
424B5
6gh075m86g okyn
5 Jan 24
Prospectus supplement for primary offering
5:15pm
424B5
b878ww6hfkwuiv
4 Jan 24
Prospectus supplement for primary offering
6:24pm
S-3ASR
o2bqdqi
8 Sep 23
Automatic shelf registration
4:31pm
8-K
otzaivhrrw9p3sgrg
21 Jul 23
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:30pm
8-K
EX-10.1
1p826i24 tl
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
8-K
dex0xoxvei 6b
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
8-K
EX-2.1
dzy5n9g10jhp8uia
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-10.2
ha6gguapw0eve
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm